News
08-06-2015, 04:16 AM
A genetic test for PIK3CA mutations may help to identify patients with HER2-positive breast cancer who are less likely to benefit from combination anti-HER2 therapy, according to a study published in The Oncologist on August 5, 2015.
More... (http://www.news-medical.net/news/20150806/Genetic-test-may-help-identify-better-treatment-option-for-HER2-positive-breast-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20150806/Genetic-test-may-help-identify-better-treatment-option-for-HER2-positive-breast-cancer-patients.aspx)